Cambridge, Massachusetts-based Biogen Inc. (BIIB) is a biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. It is\u00a0valued at a market cap of $27.7 billion.<\/p>\n
Companies worth $10 billion or more are typically classified as \u201clarge-cap stocks,\u201d and\u00a0Biogen\u00a0fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers – general industry. Beyond its core neurology focus, the company is actively expanding its pipeline across immunology and rare diseases, leveraging cutting-edge modalities like antisense oligonucleotides (ASOs) to address high unmet medical needs.<\/p>\n
This\u00a0healthcare company is currently trading 5.5% below its\u00a052-week high of $202.41, reached on Feb. 6. Shares of BIIB\u00a0have\u00a0gained 10.8% over the past three months, outperforming the State Street Health Care Select Sector SPDR ETF\u2019s (XLV)\u00a0marginal drop during the same time frame.<\/p>\n Moreover, on a YTD basis, shares of BIIB are up 8.6%, compared to XLV\u2019s 1.4% fall. In the longer term, Biogen\u00a0has soared 33.1%\u00a0over the past 52 weeks, notably outpacing XLV\u2019s 4.6% uptick over the same time frame.<\/p>\n To confirm its bullish trend,\u00a0BIIB has been\u00a0trading above its 200-day moving average since late August and has remained above its 50-day moving average since mid-August, with slight fluctuations.<\/p>\n On Feb. 6, BIIB shares\u00a0advanced 8.5% following its\u00a0stronger-than-expected Q4 earnings release. The company\u2019s revenue declined 7.1% year over year to $2.3 billion, but surpassed the $2.2 billion analyst estimate. Meanwhile, its adjusted EPS came in at $1.99, handily exceeding consensus expectations of $1.63. Management credited the quarter\u2019s performance to strong momentum in its newer product portfolio, particularly Leqembi, Skyclarys, Zurzuvae, and Qalsody, which together generated\u00a0more than $1 billion in annual revenue.<\/p>\n BIIB has outperformed its rival, Amgen Inc. (AMGN), which\u00a0gained 18.4% over the past 52 weeks. However, it has lagged AMGN\u2019s 15.3% YTD rise.<\/p>\n Given Biogen\u2019s recent outperformance, analysts remain moderately optimistic about its prospects.\u00a0The stock has a consensus rating of “Moderate Buy\u201d from the 35 analysts covering it, and the\u00a0mean price target of $206.66 suggests an 8.6% premium to its current price levels.<\/p>\n On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>